NCT03718234View on ClinicalTrials.gov

Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

February 23, 2023

Study Completion Date

February 23, 2023

Conditions
Congenital Adrenal HyperplasiaHyperplasiaAdrenal HyperplasiaCongenital DisordersAdrenocortical HyperfunctionDisorders of Sex DevelopmentUrogenital AbnormalitiesGenetic Diseases, InbornSteroid Metabolic Diseases, InbornAdrenal Gland DiseaseHydrocortisone
Interventions
DRUG

Subcutaneous hydrocortisone

Pulsatile subcutaneous hydrocortisone administered in 8 doses per day via SQ infusion pump for 6 weeks

Trial Locations (1)

55455

Prism Clinical Research, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT03718234 - Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia | Biotech Hunter | Biotech Hunter